| December 6, 2017 |
Webinar: Application of β-Arrestin Assays to the Orphan GPCR World - 30 min.
|
Login to view
|
Login to view
|
| August 16, 2017 |
Webinar: Discovery of Bacterial Effectors in the Human Microbiome and Isolation of a GPCR G2A/GPR132 Agonist - 30 min.
What will be covered?
- The role of GPCRs in regulating host-microbial interactions
- How to identify microbial metabolites that modulate GPCR functions
- A case study on defining host-microbial interaction and therapeutic potential of N-acyl amides, bacterial metabolites that activate GPR132/G2A
|
Login to view
|
Login to view
|
| April 5, 2017 |
Webinar: From Chemistry to Clinic: Discovery of Biased Apelin Receptor Agonists and Action in the Cardiovascular System - 55 min.
What will be covered?
- Role of GPCRs in human cardiovascular system
- Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
- Identifying biased agonists using pharmacologically-relevant functional cell based assays
- Validating assays and minimizing inter-assay variation
|
Login to view
|
Login to view
|
| March 9, 2017 |
Webinar: Mu Opioid Receptor Splicing and Signaling: Another Dimension of GPCR Function - 55 min.
What will be covered?
- Overview of the mu opioid receptor signaling
- GPCR splicing, using OPRM1 as an example
- Region and cell specific splicing
- Functional consequences of 5’ splicing
- Functional consequences of 3’ splicing
|
Login to view
|
Login to view
|
| November 9, 2016 |
Webinar: Duplexed Screening of GPCRs to Measure Calcium and β-Arrestin - 60 min.
What will be covered?
- Screening approaches for GPCR drug discovery
- Creating a duplexed assay to monitor calcium and β-arrestin in a single well
- Determine potential bias for various drugs and define potency ranking
|
Login to view
|
Login to view
|
| May 19, 2016 |
Webinar: Ready-to-use Potency Assays for Anti-VEGF Drugs Like Bevacizumab, Ranibizumab & Aflibercept - 60 min.
What will be covered?
- Creation of cell-based bioassays for potency and stability testing
- Application, development and validation of assays with drug molecule
- Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
- Qualified assays for > 30 biosimilars
|
Login to view
|
Login to view
|